Nuformix Announces MHRA Approval to Commence NXP001 Human Pharmacokinetics Studies

Cambridge, UK – 27th February 2019

Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) to commence human pharmacokinetics studies for the Company’s lead asset NXP001.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH